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Abstract
Introduction Tumor necrosis factor is a pleiotropic cytokine with
potent immune regulatory functions. Although tumor necrosis
factor inhibitors have demonstrated great utility in treating other
autoimmune diseases, such as rheumatoid arthritis, there are
conflicting results in Sjögren's syndrome. The aim of this study
was to assess the effect of a locally expressed tumor necrosis
factor inhibitor on the salivary gland function and histopathology
in an animal model of Sjögren's syndrome.
Methods Using in vivo adeno associated viral gene transfer, we
have stably expressed soluble tumor necrosis factor-receptor 1-
Fc fusion protein locally in the salivary glands in the Non Obese
Diabetic model of Sjögren's syndrome. Pilocarpine stimulated
saliva flow was measured to address the salivary gland function
and salivary glands were analyzed for focus score and cytokine
profiles. Additionally, cytokines and autoantibody levels were
measured in plasma.
Results Local expression of tumor necrosis factor-receptor
1:immunoglobulin G fusion protein resulted in decreased saliva
flow over time. While no change in lymphocytic infiltrates or
autoantibody levels was detected, statistically significant
increased levels of tumor growth factor-β1 and decreased levels
of interleukin-5, interleukin-12p70 and interleukin -17 were
detected in the salivary glands. In contrast, plasma levels
showed significantly decreased levels of tumor growth factor-β1
and increased levels of interleukin-4, interferon-γ, interleukin-10
and interleukin-12p70.
Conclusions Our findings suggest that expression of tumor
necrosis factor inhibitors in the salivary gland can have a
negative effect on salivary gland function and that other
cytokines should be explored as points for therapeutic
intervention in Sjögren's syndrome.
Introduction
Sjögren's syndrome (SS) is a systemic autoimmune disorder
affecting secretory tissue, including the lacrimal and salivary
glands (SGs), resulting in keratoconjunctivitis sicca and xeros-
tomia. SS is characterized by mononuclear cell infiltrates in the
salivary and lacrimal glands as well as the presence of autoan-
tibodies in serum. Other organ systems may be involved as
well and around 5% of the patients develop B cell lymphoma
ANA: antinuclear antibody; APC: antigen presenting cell; BSA: bovine serum albumin; BW: bodyweight; CMV: cytomegalovirus; CsCl: cesium chlo-
ride; CTL: cytotoxic T lymphocyte; FBS: fetal bovine serum; H&E: hematoxylin & eosin; HRP: horseradish peroxidase; IDDM: insulin-dependent dia-
betes mellitus; IFN-γ: interferon-γ; IL: interleukin; IM: intramuscular; ITR: inverted terminal repeat; LT-α: lymphotoxin-α; MCP: monocyte 
chemoattractant protein; MNV: mouse norovirus; MPV: mouse parvovirus; MVM: minute virus of mice; NOD: non obese diabetic; PBS: phosphate 
buffered saline; Q-PCR: quantitative-polymerase chain reaction; rAAV: recombinant adeno associated virus; RA: rheumatoid arthritis; SC: subcuta-
neous; SG: salivary gland; SpA: spondyloarthritis; SS: Sjögren's syndrome; TCR: T cell receptor; TGF-β: tumor growth factor-β; TNF: tumor necrosis 
factor; TNFR1:IgG: tumor necrosis factor receptor type 1 coupled to the Fc part of Immunoglobulin G; VIP: vasoactive intestinal peptide; WEHI: 
human fibrosarcoma cells.Arthritis Research & Therapy    Vol 11 No 6    Vosters et al.
Page 2 of 11
(page number not for citation purposes)
[1,2]. There is still an unmet need for an effective treatment of
SS.
Anti-tumor necrosis factor (TNF) therapies have been widely
and successfully used several chronic autoimmune diseases,
such as rheumatoid arthritis (RA) and Crohn's disease. Clinical
trials with anti-TNF antibodies and etanercept showed
improvement in 60 to 70% of the RA patients [3,4]. Patients
with SS have been reported to have elevated serum pro-
inflammatory cytokine levels compared with normal volunteers
[5,6] and TNF is also overexpressed in the SGs of SS patients
[7]. However, the use of anti-TNF agents in patients with the
autoimmune disease SS has shown conflicting results [8,9].
Beneficial results were shown in an open study, while ineffi-
cacy of anti-TNF was shown in a randomized, double-blind,
placebo-controlled trial.
TNF promotes inflammation by stimulating and inducing other
inflammatory cytokines and adhesion molecules and is a key
player in the cytokine balance [4]. In contrast, TNF can also
exhibit anti-inflammatory activities, for instance by blocking the
development of autoreactive T cells [10]. Moreover, adoptive
transfer of ex vivo TNF treated splenocytes from autoimmune
diabetic female non-obese diabetic (NOD) mice into irradiated
pre-diabetic male mice prevented the development of hyperg-
lycemia in 80% of the recipients. Recently, a T-cell based
mechanism has been proposed to explain the dual effect of
anti-TNF therapy in the treatment of autoimmune diseases in
which TNF can function as a pro-inflammatory cytokine as well
as an anti-inflammatory immunoregulatory molecule by altering
the balance of regulatory T cells [11].
The National Institute of Dental and Craniofacial Research
(NIDCR) Sjögren's clinic has previously investigated the effi-
cacy of systemic etanercept treatment in SS patients and
could not demonstrate clinical benefit [12]. Follow-up studies
of cytokine levels in these patients before and after treatment
revealed no decrease in TNF and other pro-inflammatory
cytokines [13,14]. The reasons for the failed clinical trials are
not well understood, but it is conceivable that the effects
would be different if a more localized approach was used.
Gene therapy offers the possibility to engineer cells to express
therapeutic proteins locally at high levels. Previously, we
reported successful gene transfer of interleukin (IL)-10 and
vasoactive intestinal peptide (VIP) to mouse SGs [15,16]. To
investigate the effects of local TNF blockade using gene ther-
apy, we evaluated the effect of a locally expressed TNF inhibi-
tor on the SG function and histopathology in the NOD model
of SS.
Materials and methods
Cell lines
Human embryonic kidney 293T cells were grown in DMEM
(Invitrogen, Carlsbad, CA, USA). This medium was supple-
mented with 10% heat-inactivated fetal bovine serum (FBS,
Life Technologies, Rockville, MD, USA), 2 mM L-glutamine,
penicilline (100 U/ml), and streptomycin (100 μg/ml; Biofluids,
Rockville, MD, USA) as previously described [15]. Human fib-
rosarcoma (WEHI) cells were grown in RPMI 1640 (Invitro-
gen). This medium was supplemented with 10% FBS, 2 mM
L-glutamine, penicilline (100 U/ml) and streptomycin (100 μg/
ml), gentamycin (10 mg/ml; Invitrogen) and 1 M hepes
(Invitrogen).
Construction, expression and biological activity of 
plasmid
We previously reported the construction of recombinant
Adeno Associated Virus (rAAV)-β galactosidase (rAAV2-
LacZ) encoding β-galactosidase [17]. In this study we used
the extra-cellular domain of human 55 kDa Tumor Necrosis
Factor Receptor type 1 (hTNFR1; p55) coupled to the Fc-part
of mouse Immunoglobulin G1 (IgG1), kindly provided by Dr J.
Kolls [18]. This gene was cloned into the rAAV plasmid con-
taining a Cytomegalovirus (CMV) promoter and the Inverted
Terminal Repeat (ITRs) sequences for AAV serotype 2
(AAV2). The resulting plasmid (pAAV2-CMV-hTNFR1-mIgG1)
was transfected into 293T cells and secretion of the protein in
the supernatant was measured by western blotting and an
ELISA-kit for hTNFR1 (R&D systems, Minneapolis, MN, USA).
The biological activity was measured in an assay using WEHI
fibrosarcoma cells. This assay is based on the cytotoxic effect
of TNF-α on WEHI and the neutralizing effect of soluble
hTNFR1 on bioactive TNF [19].
Vector production
To generate rAAV serotype 2 vectors (rAAV2), we used the
adenoviral helper packaging plasmid pDG. Plates (15 cm) of
approximately 40% confluent 293 T cells were cotransfected
with either pAAV-LacZ, pAAV-TNFR1 or pAAV-Luc and pDG
according to standardized methods [20]. Clarified cell lysates
were adjusted to a refractive index of 1.372 by addition of
Cesium Chloride (CsCl) and centrifuged at 38,000 rpm for 65
hr at 20°C [21]. Equilibrium density gradients were fraction-
ated and fractions with a refractive index of 1.369 to 1.375
were collected. The titer of DNA physical particles in rAAV
stocks was determined by Quantitative-Polymerase Chain
Reaction (Q-PCRand the vectors were stored at -80°C. On
the day of vector administration to NOD mice, the vector was
dialyzed for 3 hr against saline.
Animals
Female NOD mice used in this study were obtained from the
University of Florida College of Medicine, Department of
Pathology, Immunology and Laboratory Medicine. All the mice
were bred and maintained under specific pathogen free con-
ditions in the animal facilities of the National Institute of Molec-
ular Physiology and Therapeutics Branch (MPTB). All the
animals were kept under specific conditions as described in
Table 1. Animal protocols were approved by MPTB Animal
Care and Use Committee and the National Institutes of HealthAvailable online http://arthritis-research.com/content/11/6/R189
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(NIH) Biosafety Committee. All mice received water and food
ad libitum. Blood glucose levels were measured by tail cut
once a week starting at 12 weeks of age, using a OneTouch
monitor (LifeScan, Milpitas, CA, USA). Mice with blood glu-
cose levels >400 mg/dl were treated by subcutaneous injec-
tion (1 U/24 h) with long acting Humalin N (Eli Lilly,
Indianapolis, IN, USA). The blood sugar level was monitored
previously in other studies with NOD mice and does not
appear to affect their behavior, feeding activity, or SG activity
compared with non-diabetic NOD mice [15].
rAAV2 vector administration and plasma/saliva 
collection
Vectors were delivered into the submandibular glands by ret-
rograde instillation as previously described [15]. Briefly, mild
anesthesia was induced by ketamine (100 mg/mL, 1 mL/kg
body weight (BW); Fort Dodge Animal Health, Fort Dodge, IA,
USA) and xylazine (20 mg/mL, 0.7 mL/kg body weight; Phoe-
nix Scientific, St. Joseph, MO, USA) solution given intramus-
cularly (im). Ten minutes after im injection of atropine (0.5 mg/
kg BW; Sigma, St. Louis, MO, USA), female NOD mice at the
age of eight weeks were administered 50 μl vector into both
submandibular glands by retrograde ductal instillation (1 ×
1010 particles/gland) using a thin cannula (Intermedic PE10,
Clay Adams, Parsippany, NJ, USA). The vector dose was cho-
sen based on previously published results, which showed
detectable transgene activity above 109 particles/gland [15].
Saliva collection was done at several time points: baseline (six
weeks of age), 16, 20 and 24 weeks of age. Mice were anes-
thetized as described above and saliva secretion was induced
by subcutaneous (sc) injection of pilocarpine (0.5 mg/kg BW;
Sigma-Aldrich, St. Louis, MO, USA). Stimulated whole saliva
was gravimetrically collected for 20 minutes from the oral cav-
ity with a hematocrit tube (Drummond Scientific Company,
Broomall, PA, USA) placed into a preweighed 0.5 ml micro-
centrifuge tube, and the volume was determined by weight as
previously described [15]. The presented saliva data are the
result of two independent experiments (N = 20 for LacZ and
N = 19 for TNFR1:IgG). Blood was collected at the saliva col-
lection time points by retro-orbital plexus bleeding, from which
plasma was separated by centrifugation for five minutes in an
eppendorf tube centrifuge. Plasma was stored at -80°C until
further analysis.
Histologic assessment of submandibular glands
Submandibular glands were removed for histologic analysis
from NOD mice at the time of sacrifice, 24 weeks of age, and
placed overnight in 10% formalin. After fixation, the tissues
were dehydrated in ethanol series and embedded in paraffin
according to standard techniques. Sections were cut at 5 μm
with 50 μm between consecutive sections and subsequently
stained with hematoxylin and eosin (H&E). Histopathologic
scoring was performed using the focus score system in which
a focus is defined as an aggregate of 50 or more lymphocytes.
A total of three sections per SG were scored and the results
were calculated and expressed as foci per 4 mm2. The focus
scores were assessed blindly by three different examiners (JV,
HY, NR) and the mean scores were determined.
Immunohistochemistry
Infiltrating lymphocytic cells were phenotyped on frozen SG
sections by immunohistochemistry with antibodies directed
towards CD4 (clone L3T4, eBioscience, San Diego, CA,
USA), CD8 (clone 53-6.7, eBioscience), CD19 (clone ID3,
BD, Breda, The Netherlands), and CD138 (clone 281-2, BD,
Breda).
Table 1
Specific conditions for NOD mice
Food Teklad Global 18% Protein Rodent Diet (2018S), Harlan
Water Autoclaved
Bedding Care fresh (non-bleached)
Day/Night light cycle 14/10 hours
Racks Vented heap-filtered microisolator
Cage changing 1/week
Cleaning agents Clidox 1:18:1
Cage set up Autoclaved
Helicobacter Tested negative
MPV Tested negative
MVM Tested negative
MNV Tested negative
MPV = mouse parvovirus, MVM = minute virus of mice, MNV = mouse norovirus.Arthritis Research & Therapy    Vol 11 No 6    Vosters et al.
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Sections were blocked with endogenous peroxidase with 1%
H2O2. Aspecific binding was reduced by blocking with PBS
(phosphate buffered saline)/1% BSA (Bovine Serum Albumin)
+ 10% goat serum for 30 minutes at room temperature (RT).
After blocking, the sections were incubated with primary anti-
body at 4°C overnight (O/N). Stainings were visualised with a
horseradish peroxidise (HRP)-labelled goat-anti-rat secondary
antibody (Southern Biotechnology, Birmingham, AL, USA) and
developed by AEC substrate (Dako, Glostrup, Denmark). Con-
centration- and isotype-matched control antibodies were
included as negative control. All sections were coded and ran-
domly analyzed by computer-assisted image analysis. For all
markers, 18 high-power fields were analyzed. The images of
the high-power fields were analyzed using the Qwin analysis
system (Leica, Cambridge, UK), as described previously [22].
Positive staining of the cellular markers was expressed as the
number of positive cells/mm2.
Quantification of cytokine profiles
The levels of several cytokines were determined after extrac-
tion of soluble protein from the SGs. After measuring the wet
weight, SGs were homogenized in protease buffer PBS and
complete protease inhibitor cocktail (Roche Applied Science,
Indianapolis, IN, USA). The excessive connective tissue and
large aggregate debris were removed by 15 minutes centrifu-
gation at 1500 × g. Total protein in the supernatant was deter-
mined with BCA™ protein assay kit (Pierce, Rockford, IL, USA)
according to the manufacturer's instructions. Human sTNFR1
was measured by a commercial available ELISA kit (R&D
Duokit, Minneapolis, MN, USA). mIL-4, mIL-5, mIL-6, mIL-10,
mIL-12p70, mIL-17, MCP-1, mTGF-β1, mIFN-γ and mTNF-α
were measured commercially using SearchLight proteome
assay (Pierce Biotechnology, Woburn, MA, USA). This assay
is a multiplexed sandwich ELISA procedure for detecting mul-
tiple cytokines in the same minimal sample. The same analytes
were determined in plasma samples. Lower detection limits for
this assay are: mIL-4: 1.2 pg/ml, mIL-5: 2.3 pg/ml, mIL-6: 5.5
pg/ml, mIL-10: 1.6 pg/ml, mIL-12p70: 0.78 pg/ml, mIL-17: 1.6
pg/ml, MCP-1: 0.78 pg/ml, mTGF-β1: 6.8 pg/ml, mIFN-γ: 7.8
pg/ml, mTNF-α: 3.1 pg/ml.
Determination of autoantibodies
Plasma samples of 24 wk old NOD mice were analyzed for
autoantibodies against nuclear antigens (ANA), Sjögren's syn-
drome (SS) A/Ro and SSB/La. ANA (total Ig), the autoanti-
body against SSA/Ro (total Ig) and SSB/La (total Ig) were
measured by a commercial available ELISA kit (Alpha Diag-
nostic International, San Antonio, TX, USA) according the
manufacturer's protocol.
Statistical analysis
Differences in salivary flow, cytokines and lymphocytic cell
type characterization among experimental groups were
assessed using the non-parametric Wilcoxon's ranksum test.
The focus scores and autoantibodies were assessed using
unpaired Student's t-test to compare differences between
groups. Non-parametric correlations were assessed using
Spearman's Rho test and was performed with SPSS for Win-
dows (SPSS version 16.0.02, Chicago, IL, USA) and all the
other analyses were performed with GraphPad Prism statisti-
cal software (GraphPad Software Inc. version 4.02, La Jolla,
CA, USA) using a P  value less than 0.05 as statistically
significant.
Results
Biological activity of TNFR1:IgG
Prior to stable expression of TNFR1:IgG in the SGs of NOD
mice, we confirmed that the fusion protein was biologically
active in blocking TNF activity in vitro. To test for biologic activ-
ity of TNFR1:IgG, dilutions of supernatant from TNFR1:IgG
expressing cells were preincubated with 62.5 pg/ml hTNF,
this mixture was added to WEHI cells (a TNF sensitive cell
line) overnight, and cell death was measured. In the absence
of TNFR1:IgG, 62.5 pg/ml hTNF was sufficient to kill 100% of
the cells. Increasing amounts of TNFR1:IgG showed an inhib-
itory effect on TNF induced apoptosis in WEHI cells (Figure 1)
suggesting TNFR1:IgG was able to block TNF activity in vitro.
Although not tested in this study, previous studies have dem-
onstrated the efficacy of human TNFR1 on inhibiting rodent
TNF-α in animal models of autoimmune diseases [23,24].
Autoimmune diseases in female NOD
For over two years we have maintained a colony of NOD mice
under defined conditions and carefully monitored the onset of
both diabetes and change in SG function. Blood glucose lev-
els were monitored starting from 12 weeks of age and the
Figure 1
In vitro biological activity assay for TNFR1:IgG In vitro biological activity assay for TNFR1:IgG. The biological activity 
of the TNFR1:IgG was determined by adding supernate from 
TNFR1:IgG expressing cells to WEHI fibrosarcoma cells and measur-
ing its ability to block TNF induced apoptosis in these cells. Increasing 
concentrations of TNFR1:IgG resulted in inhibiting TNF (62.5 pg/ml) 
induced apoptosis of WEHI cells. Data shown are mean ± SD (N = 2 
independent experiments).Available online http://arthritis-research.com/content/11/6/R189
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mice were administered daily insulin when they became hyper-
glycemic (>400 mg/dl). SG activity was monitored by measur-
ing the change in volume of pilocarpine stimulated saliva flow
over 20 minutes with respect to BW at 6, 16, 20 and 24
weeks.
The incidence of hyperglycemia increased with age, starting at
week 16 (Figure 2A, untreated). At 24 weeks of age, 75% of
the mice were hyperglycemic. In contrast, no change in SG
activity was detected in these mice (Figure 2B, untreated).
Stimulated salivary flow was initiated by subcutaneous injec-
tion of 0.5 mg/kg BW pilocarpine and saliva was collected by
capillary tube over 20 minutes. At six weeks of age, the mean
saliva volume was 2.81 ± 0.72 μl/g BW (mean ± SEM). Mean
saliva volume increased over time to 3.96 ± 0.78 and 4.63 ±
0.69 μl/g BW at 16 weeks and 20 weeks respectively. At the
end of the study (24 weeks), the mean saliva volume
decreased slightly to 3.52 ± 1.08 μl/g BW, but was not lower
than the six week value and no statistically significant differ-
ence was measured at any time point. Moreover, these mice
developed sialadenitis with a mean focus score of 2.2 (Figure
3A). This phenotype has been confirmed over multiple gener-
ations of mice with similar results suggesting a stable pheno-
type in this environment. Furthermore, these measures are
independent of the diabetic state of the mouse at these time
points.
TNFR1:IgG expression in the salivary gland does not 
affect the rate of hyperglycemia or bodyweight
Stable TNFR1:IgG expression in the SGs was achieved by
cannulation of the glands and retrograde delivery of the Adeno
Associated Virus (AAV) vector encoding either TNFR1:IgG
(rAAV2-hTNFR1-mIgG1) or a control vector expressing β-
galactosidase (rAAV2-LacZ) to both submandibular SGs of
eight-week-old mice (N = 20 mice in the LacZ group and N =
21 mice in the TNFR1:IgG group). Vector DNA was detected
by Q-PCR on extracted total DNA from 20-week-old SGs con-
firming gene transfer (data not shown) and human sTNFR1
was detected in extracted protein confirming protein expres-
sion (Table 2). Blood sugar levels were followed starting at 12
weeks of age. In two independent experiments, between 14
weeks and 19 weeks of age the TNFR1:IgG treated group did
not show a statistically significant difference in the rate of
IDDM compared with the LacZ treated group. At 14 weeks of
age, an average of 18% of the animals receiving TNFR1:IgG
showed hyperglycemia (blood sugar >400 mg/dl) compared
with 16% in the vector control group and by 24 weeks 73% in
both vector treated groups had severe hyperglycemia (Figure
2A). This incidence of IDDM was similar to our historic rate in
untreated mice (Figure 2A).
Increased disease activity can cause growth retardation;
therefore bodyweights were measured in the vector treated
groups between 6 and 24 weeks of age and compared to
untreated mice. We saw a normal age-dependent increase in
Figure 2
Diabetes, saliva flow, and body weight in untreated and vector treated  groups Diabetes, saliva flow, and body weight in untreated and vector 
treated groups. A) Blood sugar was monitored starting at week 13 
(five weeks post vector delivery) as described in the Materials and 
Methods section. Data shown are the mean percentage from two inde-
pendent experiments (N = 8 for untreated, N = 20 for LacZ and N = 19 
for TNFR1:IgG). B) Saliva was collected as described in the Materials 
and Methods section over a 20-minute period after stimulation with 0.5 
mg/kg BW pilocarpine. Data shown are mean values +/- SEM (N = 8 
for untreated, N = 20 for LacZ and N = 19 for TNFR1:IgG). P-values 
are indicated and were determined by non-parametric Wilcoxon's rank-
sum test. Delivery of TNFR1:IgG resulted in significant decreased 
saliva flow not seen in control groups. C) The weight of the mice (in 
grams) was measured at the indicate times for LacZ, TNFR1:IgG, and 
untreated mice. There were no significant changes in bodyweight 
between all three groups as determined by unpaired student's t-test. 
Data shown are the mean (+/- SD) of two independent experiments (N 
= 8 for untreated, N = 11 for LacZ and N = 12 for TNFR1:IgG per 
experiment).
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bodyweight over time in all three groups, with no significant dif-
ferences between the groups (Figure 2C). These results sug-
gest that stable TNFR1:IgG expression in the SGs does not
affect the rate of hyperglycemia or bodyweight in NOD mice.
Stimulated saliva flow is inhibited by TNFR1:IgG 
treatment
To investigate the effect of TNFR1:IgG expression on SG
function, stimulated saliva flow was measured at 6, 16, 20 and
24 weeks. Before vector delivery, the mean saliva volume/
gram BW was measured in each group. At six weeks of age,
the mean volumes for the LacZ (N = 20) and TNFR1:IgG (N =
21) groups were 3.88 ± 0.32 and 4.30 ± 0.49 μl/g BW
respectively. After vector delivery, the saliva volumes within the
control group followed a similar course observed in our longi-
tudinal studies in untreated mice (Figure 2B). There was no
significant difference (P = 0.6111) between the mean saliva
volume before vector delivery and at 24 weeks (16 weeks post
cannulation). In contrast, the saliva volume decreased at all
time points in mice receiving TNFR1:IgG compared with the
baseline value (4.65 ± 0.32 μl/g BW) prior to cannulation. Sal-
ivary flows were 4.04 ± 0.49, 3.80 ± 0.29 and 2.67 ± 0.48 μl/
g BW at 16, 20 and 24 weeks, respectively (Figure 2B). Stim-
ulated saliva volumes of animals at 20 and 24 weeks receiving
TNFR1:IgG locally in both submandibular glands were signifi-
cantly decreased compared to their baseline levels (P  =
0.0302 and P = 0.0038 respectively). We were unable to
detect any correlation between saliva volumes and blood glu-
cose levels in individual NOD mice (data not shown). These
data suggest that expression of a TNF inhibitor in the SGs of
NOD mice results in decreased salivary flow.
The effect of TNFR1:IgG therapy on inflammation in the 
salivary glands
To determine if this loss of SG activity was the result of autoim-
mune activity in the glands, we compared the number of focal
infiltrations of inflammatory cells within the SGs [25]. Sections
from the submandibular glands of TNFR1:IgG (N = 6) and
LacZ (N = 8) treated mice sacrificed at 24 weeks were exam-
ined histologically with H&E staining to assess inflammatory
infiltrates. The focus score (mean ± SD) of mice receiving
TNFR1:IgG (2.68 ± 0.42) compared with 2.27 ± 0.43 and
2.17 ± 0.97 for mice receiving LacZ or untreated respectively
was slightly increased (Figure 3A). This increase in focus
score was not statistically significant when assessed by one-
way ANOVA (P = 0.4256, not shown). Thus far, our findings
suggest no difference in SG activity or histology as a result of
AAV vector delivery or LacZ expression which is in agreement
with previous studies [15,16]. Therefore, we decided to col-
lect cytokine data from the LacZ vector treated groups to
focus on any cytokine changes that were the result of expres-
sion of the hTNFR1 study drug.
In addition to scoring the number of foci, infiltrating lym-
phocytes were phenotyped in both vector treated groups. For
Figure 3
Focus score and infiltrate analysis in untreated and vector treated  groups Focus score and infiltrate analysis in untreated and vector treated 
groups. A) Salivary glands were removed for histologic analysis at 24 
weeks, fixed and stained with Hematoxylin and eosin. Histopathologic 
assessment was performed and presented as a focus score (see Mate-
rials and Methods). Data shown are the mean (+/- SD). No significant 
change was detected by one-way ANOVA test followed by unpaired 
student's t-test. Untreated (N = 7), LacZ (N = 8) and TNFR1:IgG (N = 
6) mice. B) Acetone fixed frozen sections from SGs were analyzed for 
CD4, CD8, CD19 and CD138 by immunohistochemistry followed by 
digital analysis as described in the Material and Methods section. Data 
shown are the mean positive cell counts per mm2 (+/- SEM). Higher 
means were observed for CD4, CD8 and CD138 in the TNFR1:IgG 
treated mice, but no significant changes were detected by non-para-
metric Wilcoxon's ranksum test. LacZ (N = 4) and TNFR1:IgG (N = 8).
 Available online http://arthritis-research.com/content/11/6/R189
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both groups, CD4+ and CD8+ T lymphocytes were most
prominent followed by B (CD19+) lymphocytes and plasma
(CD138+) cells (Figure 3B). Both CD4+ and CD8+ T lym-
phocytes were slight increased in TNFR1:IgG treated mice
with 1004 ± 208 (mean positive cells/mm2 ± SEM) and 927
± 158 respectively compared to mice receiving LacZ (788 ±
115 and 782 ± 117 respectively; Figure 3B). Although with
higher variability, the same pattern was seen for plasma cells.
Control vector treated mice showed 282 ± 45 plasma cells
compared to 724 ± 227 in TNFR1:IgG treated mice. No differ-
ence for B lymphocytes was detected between the vector
treated groups (Figure 3B). All the differences detected in lym-
phocytic cell types were not statistically significant when
assessed by non-parametric Wilcoxon's ranksum test.
TNFR1:IgG expression alters cytokine levels in the 
salivary glands and plasma
To investigate if local expression of TNFR1:IgG in the SG
could change cytokine levels either systemically in the plasma
or locally in the SGs, plasma samples and SG protein extracts
were obtained from mice at 20 weeks (12 weeks post cannu-
lation) and cytokine levels were measured by multiplex analysis
(Table 2). Expression of TNFR1:IgG in the SG did not change
the level of murine TNF-α, MCP-1, or IL-6 in either plasma or
SG samples. In the SG samples, cytokines from the Th1, Th2
and Th17 lineage (mIL-12p70, mIL-5 and mIL-17) were signif-
icantly decreased in the TNFR1:IgG SG samples compared
with control samples. In contrast, we observed a significant
increase in mTGF-β1. No significant change in mIFN-γ or mIL-
4 expression in the SG samples from the TNFR1:IgG treated
group compared with the control group (Table 2). Further anal-
ysis showed a correlation between SG hTNFR1 levels and sal-
ivary flow (r = -0.833, P = 0.001; Figure 4A). Moreover, SG
mTGF-β1, IL-5, IL-12p70 and IL-17 showed also a correlation
with salivary flow (r = -0.641, P = 0.034; r = 0.604, P = 0.049;
r = 0.659, P = 0.027 and r = 0.604, P = 0.049 respectively,
data not shown).
Interestingly, many cytokines showed an opposite pattern of
expression in the plasma samples compared with the SG sam-
ples. Plasma levels of murine IL-4, IL-10, IL-12p70 and IFN-γ
were significantly increased and mTGF-β1 was significantly
decreased in the TNFR1:IgG treated mice compared with con-
trols (Table 2). IL-5 expression was also increased in plasma
TNFR1:IgG treated samples compared with the decrease in
the SG sample but the change was not statistically significant.
In contrast to the SG samples, IL-17 in the plasma remained
unchanged. Also, plasma IL-12p70 showed a correlation with
salivary flow (r = -0.843, P = 0.001, Figure 4B). Similar results
were obtained for plasma IL-4 (r = -0.889, P < 0.001, Figure
4C), IL-5 (r = -0.838, P = 0.001, Figure 4D), and IFN-γ (r = -
0.682, P = 0.021, data not shown). These data imply a local
effect of TNF-inhibitors, showing increased levels of TGF-β1
and decreased levels of IL-5, IL-12p70 and IL-17 in SGs,
accompanied by decreased levels of TGF-β1 and increased
levels of IL-4, IFN-γ, and IL-12p70 in plasma. Correlation anal-
ysis also suggests that changes in expression of several of
these cytokines may be closely linked with changes in salivary
gland activity as measured by changes in salivary flow rates
(Figure 4).
Table 2
Cytokines in salivary gland extract and plasma
Salivary gland extract
(pg/ml per 20 mg wet SG)
Plasma (pg/ml)
LacZ TNFR1:IgG P value LacZ TNFR1:IgG P value
mTNF-α 73.0 (53.0) 24.6 (2.5) 0.9273 21.2 (5.3) 45.5 (15.3) 0.3152
MCP-1 325.0 (222.7) 254.6 (70.6) 1.0000 182.0 (49.0) 95.1 (10.8) 0.0727
mIL-4 23.0 (12.2) 3.8 (1.0) 0.0727 1.2 (0.05) 16.1 (2.3) *0.0061
mIL-5 94.5 (41.4) 7.3 (1.9) *0.0061 2.3 (0.04) 30.7 (8.3) 0.0727
mIL-6 109.9 (61.4) 42.4 (15.2) 0.3152 20.7 (8.8) 37.0 (5.7) 0.1636
mIFN-γ 657.9 (305.5) 614.9 (216.1) 0.5273 192.9 (28.5) 511.7 (75.0) *0.0061
mIL-10 37.6 (14.8) 7.7 (2.0) 0.0727 3.0 (0.4) 27.5 (3.3) *0.0061
mTGF-β1 4342 (1742) 3.0E6 (7.8E5) *0.0061 7.8E5 (8.1E4) 1840 (187.7) *0.0061
mIL-12p70 130.2 (54.3) 6.3 (2.3) *0.0061 18.3 (11.0) 65.8 (7.4) *0.0242
mIL-17 53.2 (24.3) 5.4 (1.6) *0.0242 6.4 (3.1) 12.1 (1.8) 0.1636
hTNFR1 0.0 (0.0) 114.4 (43.5) ND
Protein expression of immunomodulatory molecules after administration of LacZ and TNFR1:IgG in salivary gland extract and plasma. Data shown 
are mean values +/- SEM. Significant differences are indicated (*) and were determined by non-parametric Wilcoxon's ranksum test. LacZ (N = 4) 
and TNFR1:IgG (N = 7). ND = not determined.Arthritis Research & Therapy    Vol 11 No 6    Vosters et al.
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The effect of TNFR1:IgG treatment on autoantibody 
formation
Sera from SS patients contain a number of identifiable autoan-
tibodies directed against nuclear, cytoplasmic and cell surface
components. Autoantibodies have also been reported to
occur in patients receiving anti-TNF therapy and in NOD mice
[1,26-28]. Therefore, we compared autoantibody levels in
plasma samples from untreated 6 week old mice (N = 4,
pooled), 24 weeks old TNFR1:IgG (N = 6) treated and control
LacZ (N = 8) treated mice. As shown in Figure 4, autoantibod-
ies did increase with age but there was no clear cut difference
between the LacZ and TNFR1:IgG treated groups for anti-
SSA antibodies (Figure 5A). There was perhaps a minor trend
towards increased levels of anti-SSB (Figure 5B) and ANA
(Figure 5C), which did not reach statistical significance. These
results imply that characteristic SS autoantibodies are pro-
duced over time in NOD mice, but there is no clear cut effect
of local TNF blockade on the autoantibody profile.
Discussion
In order to better understand the local role of TNF and the
effect of TNF soluble receptor based therapies on SG activity,
we have stably expressed soluble TNFR1:IgG fusion protein
locally in the SGs of NOD mice and followed stimulated saliva
flow, sialadenitis, cytokine production, autoantibody levels,
and insulin-dependent diabetes mellitus (IDDM) over 18
weeks. This local therapy resulted in decreased stimulated
saliva flow and reduced Th1, Th2 and Th17 cytokine levels in
Figure 4
Correlation cytokines with salivary flow Correlation cytokines with salivary flow. Cytokine data were analyzed for correlation with salivary flow from mice at 20 weeks of age using the 
non-parametric Spearman's Rho test. The correlation coefficient (r) and P-values are indicated. Data on the x-axis for figure A are plotted in log-scale. 
Strong correlations were found for hTNFR1 (A) in SGs and IL-12p70 (B), IL-4 (C), IL-5 (D) in plasma.
r = -0.833
P = 0.001
C
A
r = -0.889
P < 0.001
D
B
r = -0.843
P = 0.001
r = -0.838
P = 0.001
r = -0.833
P = 0.001
C
A
r = -0.889
P < 0.001
D
B
r = -0.843
P = 0.001
r = -0.838
P = 0.001Available online http://arthritis-research.com/content/11/6/R189
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the SG accompanied by increased levels of Th1 and Th2
cytokines in plasma.
The reduced SG activity after local TNF blockade suggests a
protective role for TNF in SG function. TNF has been reported
to exhibit anti-inflammatory activities, for instance by blocking
the development of autoreactive T cells or by altering the bal-
ance of regulatory T cells [10,11]. Recently, the anti-inflamma-
tory effects of TNF were reported to be mediated through
TNFR2 in tolerogenic TGF-β treated antigen presenting cells
(APC) and blocking of TNFR1 signaling enhanced the ability
of APCs to secrete TGF-β in response to TGF-β exposure
[29]. Consistent with this notion, TNFR1:IgG treatment
resulted in increased TGF-β1 tissue levels. The unaltered IFN-
γ and MCP-1 levels suggest an IFN-γ independent pathway. In
plasma we found an opposite pattern after TNFR1:IgG treat-
ment, with increased levels of IL-4, IL-12p70 and, IFN-γ and
decreased expression of TGF-β1. Of interest, IL-12p70
(together with IFN-γ) has been reported to be elevated in
serum of SS patients [30]. Moreover, recently we have
reported salivary dysfunction in IL-12 transgenic mice, provid-
ing a new model of SS [31]. The systemic decrease of TGF-
β1 levels found in the present study is in agreement with the
SS-like lymphoproliferation seen in TGF-β KO mice [32]. Our
data indicate that systemic upregulation of IL-12p70 and
downregulation of TGF-β1 may play an important role in SS
and these cytokines might promote SG dysfunction after anti-
TNF treatment. The change in SG function after TNFR1:IgG
treatment is in line with previous observations showing that
under certain circumstances patients on anti-TNF therapy may
develop additional autoimmune complications (for example,
demyelinating events) [33-36]. TNF blockers also have been
shown to induce antinuclear antibodies (ANA) and antibodies
directed against double stranded (ds) DNA in autoimmune
diseases, such as RA, spondyloarthritis (SpA) and systemic
lupus erythematosus (SLE) [27,28].
There was no statistically significant change in focal infiltration
of the gland or autoantibody levels in our study. Similarly, we
previously found that SG activity can be affected by the local
expression of immunomodulatory proteins independent of the
focus score [16]. Additionally, phenotyping of the infiltrating
lymphocytes showed a trend to increased positive cell counts
for plasma cells, CD4+ and CD8+ T lymphocytes in
TNFR1:IgG treated SGs. Our data suggest that i) expression
of TNFR1:IgG does not impair the ability of lymphocytes to
migrate to areas of inflammation and ii) there is no clear cut
correlation between decreased saliva flow and the severity of
inflammation within the glands. A large body of literature has
determined that in rodents, AAV2 based vectors only trigger a
minimal and largely transient immune response. Although, we
have not specifically tested for the generation of anti-AAV2
antibodies or cytotoxic T lymphocytes (CTLs) in this study, the
SG activity and infiltrate scores were very similar for both
untreated mice and those cannulated with AAV2 LacZ vector,
Figure 5
Autoantibodies in plasma Autoantibodies in plasma. Plasma samples were collected and 
autoantibody levels were measured as described in the Material and 
Methods section using samples collected at 24 weeks and compared 
with four different pools of pre-disease six-week-old mice. Antibody lev-
els for SSA/Ro (A) SSB/La (B) and ANA (C) are shown (mean ± SD). 
Significant differences are indicated (*) and were determined by one-
way ANOVA test followed by unpaired student's t-test. LacZ (N = 8) 
and TNFR1:IgG (N = 6).
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suggesting the AAV2 vector itself has minimal response. In
other studies we have also used a vector that does not encode
a transgene such as LacZ and found similar results (data not
shown).
There is at present no generally accepted animal model of SS,
which represents all the features of this condition. However, in
addition to its utility in studying IDDM, the NOD mouse can
also develop other autoimmune conditions such as gender-
and age-specific mononuclear gland infiltrates and exocrine
dysfunction of salivary and lacrimal glands that resemble Sjö-
gren's syndrome [37]. We have previously used this model
successfully to demonstrate the stimulatory effect of IL-10
[15] and vasoactive intestinal peptide gene transfer [16] on
SG activity. The development of autoimmune disease in these
mice can, however, be affected by environmental and experi-
mental conditions and is also dependent on the specific sub-
strain of the NOD mice [38-40]. Over the last two years we
have maintained a colony of NOD mice under defined condi-
tions that develop sialadenitis. Consistent with our recent
observations [38], the mice developed SG infiltrates and
autoantibodies without developing a spontaneous loss of SG
activity. Also, other NOD-derived strains have been reported
as SS animal models, such as NOD.B10-H2b [41] and
C57BL/6.NOD-Aec1 Aec2 [42]. Each of these strains has
advantages compared with NOD/LTJ mice and as they
become more widely studied, may be useful models for
examining the long term effects of immunomodulatory proteins
which is difficult in NOD/LTJ mice. The results presented here
also show that local TNFR1:IgG treatment administered to the
SG does not affect the incidence of diabetes in this model.
Several studies have indicated that systemically increasing
TNF levels can prevent the onset of IDDM in NOD mice
[11,43]. Potential mechanisms include the effect of TNF on
signal transduction through the T-Cell Receptor (TCR), includ-
ing NF-κB expression, and/or a direct effect of TNF on T-cell
apoptosis in the periphery [11,44]. On the other hand, sys-
temic TNFR1:IgG treatment prevented diabetes in NOD mice
[45]. Taken together, the role of TNF in the pathogenesis of
diabetes in NOD mice is still controversial [43]. Conceivably,
the systemic levels of TNFR1:IgG in our study were too low to
influence the disease proves in the pancreas. In contrast to
TNFR2, the type 1 TNF receptor can bind both TNF-α and lym-
photoxin (LT)-α. The results shown in our experiments are
likely the result of binding both cytokines. At this point, we are
not able to distinguish between both effects and therefore
cannot conclude that the effect on gland activity is caused by
blocking TNF-α alone. Further mechanistic experiments are
needed to explain the exact role of anti-TNF in SS.
Conclusions
The data presented here do not support the notion that local
TNF blockade may have a beneficial effect in SS. In contrast,
TNF blockade might worsen SG function in this disease.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JLV and JAC designed the study. JLV, HY and NR acquired the
data. JLV, HY, PPT and JAC analyzed, interpreted and evalu-
ated the data. JLV, MRK, PPT and JAC prepared the
manuscript.
Acknowledgements
The authors thank Bruce J. Baum and Gabor G. Illei for critical review 
and helpful discussion of this manuscript and Beverly Handelman for the 
virus preparations. This work is supported by a Dutch Arthritis Associa-
tion grant [NR 07-1-406] to JLV and an NIH, NIDCR intramural research 
grant to JAC.
References
1. Fox RI: Sjogren's syndrome.  Lancet 2005, 366:321-331.
2. Van Mello NM, Pillemer SR, Tak PP, Sankar V: B cell MALT lym-
phoma diagnosed by labial minor salivary gland biopsy in
patients screened for Sjogren's syndrome.  Ann Rheum Dis
2005, 64:471-473.
3. Taylor PC: Anti-TNFalpha therapy for rheumatoid arthritis: an
update.  Intern Med 2003, 42:15-20.
4. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP: Tumor
necrosis factor antagonist mechanisms of action: a compre-
hensive review.  Pharmacol Ther 2008, 117:244-279.
5. O'Shea JJ, Ma A, Lipsky P: Cytokines and autoimmunity.  Nat
Rev Immunol 2002, 2:37-45.
6. Garcic-Carrasco M, Font J, Filella X, Cervera R, Ramos-Casals M,
Siso A, Aymami A, Ballesta AM, Ingelmo M: Circulating levels of
Th1/Th2 cytokines in patients with primary Sjogren's syn-
drome: correlation with clinical and immunological features.
Clin Exp Rheumatol 2001, 19:411-415.
7. F o x  R I,  K an g  H I,  An d o  D , A b ra ms  J ,  Pi s a E :  Cytokine mRNA
expression in salivary gland biopsies of Sjogren's syndrome.
J Immunol 1994, 152:5532-5539.
8. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E,
Combe B, Puechal X, Pennec Y, Sauvezie B, Perdriger A, Hayem
G, Janin A, Sibilia J: Inefficacy of infliximab in primary Sjogren's
syndrome: results of the randomized, controlled Trial of Rem-
icade in Primary Sjogren's Syndrome (TRIPSS).  Arthritis
Rheum 2004, 50:1270-1276.
9. Steinfeld SD, Demols P, Appelboom T: Infliximab in primary
Sjogren's syndrome: one-year followup.  Arthritis Rheum 2002,
46:3301-3303.
10. Wu AJ, Hua H, Munson SH, McDevitt HO: Tumor necrosis fac-
tor-alpha regulation of CD4+CD25+ T cell levels in NOD mice.
Proc Natl Acad Sci USA 2002, 99:12287-12292.
11. Kodama S, Davis M, Faustman DL: The therapeutic potential of
tumor necrosis factor for autoimmune disease: a mechanisti-
cally based hypothesis.  Cell Mol Life Sci 2005, 62:1850-1862.
12. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J,
Baum BJ, Pillemer SR: Etanercept in Sjogren's syndrome: a
twelve-week randomized, double-blind, placebo-controlled
pilot clinical trial.  Arthritis Rheum 2004, 50:2240-2245.
13. Moutsopoulos NM, Katsifis GE, Angelov N, Leakan RA, Sankar V,
Pillemer S, Wahl SM: Lack of efficacy of etanercept in Sjogren
syndrome correlates with failed suppression of tumour necro-
sis factor alpha and systemic immune activation.  Ann Rheum
Dis 2008, 67:1437-1443.
14. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl
SM, Crow MK: Augmented interferon-alpha pathway activation
in patients with Sjogren's syndrome treated with etanercept.
Arthritis Rheum 2007, 56:3995-4004.
15. Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar
S, Voutetakis A, Leroith D, Schmidt M, Afione S, Pillemer SR, Tsut-
sui MT, Tak PP, Chiorini JA, Baum BJ: Local adeno-associated
virus-mediated interleukin 10 gene transfer has disease-mod-
ifying effects in a murine model of Sjogren's syndrome.  Hum
Gene Ther 2003, 14:1605-1618.Available online http://arthritis-research.com/content/11/6/R189
Page 11 of 11
(page number not for citation purposes)
16. Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP,
Baum BJ: Effect of human vasoactive intestinal peptide gene
transfer in a murine model of Sjogren's syndrome.  Ann Rheum
Dis 2006, 65:195-200.
17. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA: Adeno-
associated virus serotype 4 (AAV4) and AAV5 both require
sialic acid binding for hemagglutination and efficient transduc-
tion but differ in sialic acid linkage specificity.  J Virol 2001,
75:6884-6893.
18. Peppel K, Crawford D, Beutler B: A tumor necrosis factor (TNF)
receptor-IgG heavy chain chimeric protein as a bivalent antag-
onist of TNF activity.  J Exp Med 1991, 174:1483-1489.
19. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164
clone 13, for measuring cytotoxic factor/tumor necrosis factor
from human monocytes.  J Immunol Methods 1986, 95:99-105.
20. Grimm D, Kern A, Rittner K, Kleinschmidt JA: Novel tools for pro-
duction and purification of recombinant adenoassociated
virus vectors.  Hum Gene Ther 1998, 9:2745-2760.
21. Atchison RW, Casto BC, Hammon WM: Adenovirus-Associated
Defective Virus Particles.  Science 1965, 149:754-756.
22. Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman
AH, Tak PP: Reliability of computerized image analysis for the
evaluation of serial synovial biopsies in randomized controlled
trials in rheumatoid arthritis.  Arthritis Res Ther 2005,
7:R862-867.
23. Khoury M, Adriaansen J, Vervoordeldonk MJ, Gould D, Chernajo-
vsky Y, Bigey P, Bloquel C, Scherman D, Tak PP, Jorgensen C,
Apparailly F: Inflammation-inducible anti-TNF gene expression
mediated by intra-articular injection of serotype 5 adeno-asso-
ciated virus reduces arthritis.  J Gene Med 2007, 9:596-604.
24. Adriaansen J, Khoury M, de Cortie CJ, Fallaux FJ, Bigey P, Scher-
man D, Gould DJ, Chernajovsky Y, Apparailly F, Jorgensen C, Ver-
voordeldonk MJ, Tak PP: Reduction of arthritis following intra-
articular administration of an adeno-associated virus serotype
5 expressing a disease-inducible TNF-blocking agent.  Ann
Rheum Dis 2007, 66:1143-1150.
25. Greenspan JS, Daniels TE, Talal N, Sylvester RA: The histopa-
thology of Sjogren's syndrome in labial salivary gland
biopsies.  Oral Surg Oral Med Oral Pathol 1974, 37:217-229.
26. Nguyen CQ, Cha SR, Peck AB: Sjogren's syndrome (SjS)-like
disease of mice: the importance of B lymphocytes and
autoantibodies.  Front Biosci 2007, 12:1767-1789.
27. De Rycke L, Baeten D, Kruithof E, Bosch F Van den, Veys EM, De
Keyser F: The effect of TNFalpha blockade on the antinuclear
antibody profile in patients with chronic arthritis: biological
and clinical implications.  Lupus 2005, 14:931-937.
28. Aringer M, Smolen JS: The role of tumor necrosis factor-alpha
in systemic lupus erythematosus.  Arthritis Res Ther 2008,
10:202.
29. Masli S, Turpie B: Anti-inflammatory effects of tumour necrosis
factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolero-
genic transforming growth factor-beta-treated antigen-pre-
senting cells.  Immunology 2009, 127:62-72.
30. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM:
Systemic and local interleukin-17 and linked cytokines associ-
ated with Sjogren's syndrome immunopathogenesis.  Am J
Pathol 2009, 175:1167-1177.
31. Vosters JL, Landek-Salgado MA, Yin H, Swaim WD, Kimura H, Tak
PP, Caturegli P, Chiorini JA: Interleukin-12 induces salivary
gland dysfunction in transgenic mice, providing a new model
of Sjögren's syndrome.  Arthritis Rheum 2009, 60:3633-3641.
32. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes
G, Talal N: SLE-like autoantibodies and Sjogren's syndrome-
like lymphoproliferation in TGF-beta knockout mice.  J
Immunol 1995, 155:3205-3212.
33. Sicotte NL, Voskuhl RR: Onset of multiple sclerosis associated
with anti-TNF therapy.  Neurology 2001, 57:1885-1888.
34. Enayati PJ, Papadakis KA: Association of anti-tumor necrosis
factor therapy with the development of multiple sclerosis.  J
Clin Gastroenterol 2005, 39:303-306.
35. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH,
Quinn MA, Emery P: Anti-tumor necrosis factor-alpha therapy-
induced vasculitis: case series.  J Rheumatol 2003,
30:2287-2291.
36. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Ber-
tolaccini L, Cuadrado MJ, Khamashta MA: Autoimmune diseases
induced by TNF-targeted therapies: analysis of 233 cases.
Medicine (Baltimore) 2007, 86:242-251.
37. Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K:
Impaired salivary gland function in NOD mice: Association
with changes in cytokine profile but not with histopathologic
changes in the salivary gland.  Arthritis Rheum 2006,
54:2300-2305.
38. Lodde BM, Mineshiba F, Kok MR, Wang J, Zheng C, Schmidt M,
Cotrim AP, Kriete M, Tak PP, Baum BJ: NOD mouse model for
Sjogren's syndrome: lack of longitudinal stability.  Oral Dis
2006, 12:566-572.
39. Saravia-Fernandez F, Durant S, Hasnaoui A, et al.: Environmental
and Experimental Procedures Leading to Variations in the
Incidence of Diabetes in the Nonobese Diabetic (NOD) Mouse.
Autoimmunity 1996, 24:113-121.
40. Soyfoo MS, De Vriese C, Debaix H, Martin-Martinez MD, Mathieu
C, Devuyst O, Steinfeld SD, Delporte C: Modified aquaporin 5
expression and distribution in submandibular glands from
NOD mice displaying autoimmune exocrinopathy.  Arthritis
Rheum 2007, 56:2566-2574.
41. Nguyen C, Cornelius J, Singson E, Killedar S, Cha S, Peck AB:
Role of complement and B lymphocytes in Sjogren's syn-
drome-like autoimmune exocrinopathy of NOD.B10-H2b mice.
Mol Immunol 2006, 43:1332-1339.
42. Nguyen CQ, Kim H, Cornelius JG, Peck AB: Development of
Sjogren's syndrome in nonobese diabetic-derived autoim-
mune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on
complement component-3.  J Immunol 2007, 179:2318-2329.
43. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD,
McDevitt HO: Effect of tumor necrosis factor alpha on insulin-
dependent diabetes mellitus in NOD mice. I. The early devel-
opment of autoimmunity and the diabetogenic process.  J Exp
Med 1994, 180:995-1004.
44. McDevitt H, Munson S, Ettinger R, Wu A: Multiple roles for tumor
necrosis factor-alpha and lymphotoxin alpha/beta in immunity
and autoimmunity.  Arthritis Res 2002, 4(Suppl 3):S141-152.
45. Hunger RE, Carnaud C, Garcia I, Vassalli P, Mueller C: Prevention
of autoimmune diabetes mellitus in NOD mice by transgenic
expression of soluble tumor necrosis factor receptor p55.  Eur
J Immunol 1997, 27:255-261.